# A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

> **NCT00001587** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (—)

## Conditions studied

- Liver Neoplasms
- Neoplasm Metastasis

## Interventions

- **PROCEDURE:** Isolated hepatic portal and arterial perfusion
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT00001587
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-09
- **Primary completion:** —
- **Final completion:** 2001-03
- **Target enrollment:** 30 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001587, "A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00001587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*